

For Immediate Release:

January 7, 2009

Contact:

Mary Kuramoto

513-579-9911 X 2523

m.kuramoto@medpace.com

Medpace adds Executive Medical Director, Dr. Thomas G. Todaro, MD, JD, FACC, FCLM, strengthening therapeutic expertise in cardiology

CINCINNATI (January 7, 2009) — Medpace, Inc. today announced the addition of Dr. Thomas G. Todaro, MD, JD, FACC, FCLM as an Executive Medical Director, continuing their strategy of building onto a strong existing therapeutic team of scientists. Dr. Todaro joins a group considered industry leaders in development of pharmaceuticals supporting cardiac health.

Thomas Todaro, MD, JD, FACC, FCLM is a renowned Cardiologist with over 20 years of clinical and trial experience. Before joining Medpace, Dr. Todaro worked as the Director of Global Clinical Development, Licensing and Acquisitions, for Procter & Gamble Pharmaceuticals in Mason, Ohio. Prior to that, he served as Cardiologist and President of Long Island Heart Diagnostics, PC, for six years. He was also Vice President and Director of Cardiac Rehab, PC, in New York for nearly 10 years.

“The addition of Dr. Todaro to our therapeutic group of experts contributes to an increasing level of opportunity and knowledge for our sponsors,” said Dr. August Troendle, Medpace President and CEO. “As a seasoned opinion leader, Dr. Todaro strengthens our focus in cardiology as well as providing additional depth to our already strong scientific medical monitor team.”

Dr. Todaro has conducted cardiology trials involving coronary artery bypass surgery, heart valve replacement, acute myocardial infarction with percutaneous reperfusion therapy, and other cardiac areas of interest. Dr. Todaro has also authored/co-authored numerous journal articles and several presentations for the American Heart Association and the American College of Cardiology.

###

ABOUT MEDPACE

Medpace is a leading global full-service clinical research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, oncology, and nephrology. Medpace has assembled the industry’s most experienced and therapeutically focused team to execute at every level of the company’s operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.

With more than 700 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, oncology, and nephrology.

Medpace provides centralized image management and reading from Imagepace, centralized laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology.

Visit the Medpace website at www.medpace.com